Authors:

Taha Ghazanfar

Date Created:

Not specified

Course Title:

Professor:

Not specified

About Paper:

Ovarian cancer ranks among the most lethal gynecologic malignancies. Chemotherapy has been a standard of care in treating ovarian cancer for the past two decades. Chemotherapy resistance, however, remains a major challenge in treating ovarian cancer, necessitating the search for new treatment strategies. This study evaluates the efficacy of three chemotherapeutic agents- Clofarabine (CLF), AZD5305 (Saruparib), and AZD6738 (Ceralasertib)-as single agents or in combination in chemotherapy-resistant ovarian cancer cells. Using three ovarian cancer cell lines treated with single agents or in combination, we assessed perturbed gene expression as drug responses to identify biological pathways contributing to potential synergistic effects. Bulk RNA sequencing data were analyzed through differential gene expression between groups (defined by treatments), and results were visualized by various techniques in R to identify molecular changes associated with treatment responses. Our findings indicate that cells treated with the combination of AZD6738 and CLF exhibited reduced resistance, suggesting a potential therapeutic advantage. These results provide insights into targeting chemotherapy-resistant ovarian cancer and support further investigation into combination strategies to overcome resistance. Retrospective Chart Review: Prevalent Characteristics of Hmong Patients Seen at the Hmong Lifting Underserved Barriers Clinic, a Free Student-Run Clinic in Sacramento, California John Giang

Source:

UC Davis / MED: Obstetrics & Gynecology / 2025

Topics:

No topics listed

Co-authors:

Taha Ghazanfar